Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free VRAYQ Stock Alerts

ViewRay (VRAYQ) Competitors

Compare

VRAYQ vs. SDCCQ, GMVDF, TTOO, AFIB, and UTRS

Should you buy ViewRay stock or one of its competitors? MarketBeat compares ViewRay with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ViewRay include SmileDirectClub (SDCCQ), G Medical Innovations (GMVDF), T2 Biosystems (TTOO), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "medical equipment" industry.

How does ViewRay compare to SmileDirectClub?

SmileDirectClub (NASDAQ:SDCCQ) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

SmileDirectClub has higher revenue and earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SmileDirectClub$470.74M0.00-$86.40M-$0.13N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

SmileDirectClub has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

0.1% of SmileDirectClub shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 64.7% of SmileDirectClub shares are owned by company insiders. Comparatively, 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
SmileDirectClubN/A N/A N/A
ViewRay N/A N/A N/A

In the previous week, SmileDirectClub's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
SmileDirectClub Neutral
ViewRay Neutral

Summary

SmileDirectClub beats ViewRay on 5 of the 7 factors compared between the two stocks.

How does ViewRay compare to G Medical Innovations?

ViewRay (NASDAQ:VRAYQ) and G Medical Innovations (NASDAQ:GMVDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
G Medical Innovations N/A N/A N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled G Medical Innovations'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
G Medical Innovations Neutral

G Medical Innovations has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
G Medical Innovations$4.42M0.00-$24.63MN/AN/A

ViewRay has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, G Medical Innovations has a beta of 28.55, indicating that its stock price is 2,755% more volatile than the broader market.

15.5% of ViewRay shares are held by institutional investors. Comparatively, 6.0% of G Medical Innovations shares are held by institutional investors. 2.5% of ViewRay shares are held by insiders. Comparatively, 37.1% of G Medical Innovations shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

G Medical Innovations beats ViewRay on 3 of the 5 factors compared between the two stocks.

How does ViewRay compare to T2 Biosystems?

ViewRay (NASDAQ:VRAYQ) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 2.5% of ViewRay shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

T2 Biosystems has lower revenue, but higher earnings than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
T2 Biosystems$7.68M0.00-$50.08M-$3.89N/A

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
T2 Biosystems -563.16%N/A -174.06%

In the previous week, T2 Biosystems had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for T2 Biosystems and 0 mentions for ViewRay. T2 Biosystems' average media sentiment score of 0.67 beat ViewRay's score of 0.00 indicating that T2 Biosystems is being referred to more favorably in the news media.

Company Overall Sentiment
ViewRay Neutral
T2 Biosystems Positive

ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, T2 Biosystems has a beta of 7.71, meaning that its share price is 671% more volatile than the broader market.

Summary

T2 Biosystems beats ViewRay on 6 of the 11 factors compared between the two stocks.

How does ViewRay compare to Acutus Medical?

Acutus Medical (NASDAQ:AFIB) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Acutus Medical has a beta of 5.67, indicating that its stock price is 467% more volatile than the broader market. Comparatively, ViewRay has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

ViewRay has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ViewRay's return on equity of 0.00% beat Acutus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Acutus Medical-272.74% -311.64% -11.57%
ViewRay N/A N/A N/A

In the previous week, Acutus Medical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Acutus Medical Neutral
ViewRay Neutral

Acutus Medical has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$7.16M0.00-$81.66M-$0.11N/A
ViewRay$102.21M0.00-$107.33M-$0.31N/A

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by company insiders. Comparatively, 2.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Acutus Medical and ViewRay tied by winning 5 of the 10 factors compared between the two stocks.

How does ViewRay compare to Minerva Surgical?

ViewRay (NASDAQ:VRAYQ) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

15.5% of ViewRay shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ViewRay has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Minerva Surgical has a beta of 2.92, meaning that its stock price is 192% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
Minerva Surgical N/A N/A N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled Minerva Surgical'saverage media sentiment score.

Company Overall Sentiment
ViewRay Neutral
Minerva Surgical Neutral

Minerva Surgical has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33M-$0.31N/A
Minerva Surgical$51.69M0.00-$34.11M-$4.21N/A

Summary

Minerva Surgical beats ViewRay on 4 of the 7 factors compared between the two stocks.

Get ViewRay News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAYQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAYQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAYQ vs. The Competition

Export
MetricViewRayElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$18K$70.97M$6.86B$12.25B
Dividend YieldN/AN/A2.67%9.79%
P/E Ratio0.008.5527.1423.64
Price / SalesN/A192.07517.0189.03
Price / CashN/A41.3650.5459.64
Price / BookN/A4.3310.286.07
Net Income-$107.33M-$5.50M$3.60B$331.99M

ViewRay Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAYQ
ViewRay
N/AN/AN/AN/A$18K$102.21MN/A300
SDCCQ
SmileDirectClub
N/AN/AN/AN/A$40K$470.74MN/A2,700
GMVDF
G Medical Innovations
N/A$0.00
flat		N/AN/A$26K$4.42MN/A72
TTOO
T2 Biosystems
N/A$0.00
+28.6%		N/A-99.3%$19K$7.68MN/A180
AFIB
Acutus Medical
N/AN/AN/AN/A$3K$7.16MN/A340

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRAYQ) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel